Progyny, Inc. (NASDAQ:PGNY – Get Free Report) Chairman David J. Schlanger sold 2,597 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $37.65, for a total value of $97,777.05. Following the completion of the sale, the chairman now directly owns 86,312 shares of the company’s stock, valued at $3,249,646.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Progyny Trading Up 2.6 %
PGNY stock opened at $37.99 on Thursday. Progyny, Inc. has a 52 week low of $29.44 and a 52 week high of $44.95. The firm’s 50-day moving average is $37.92 and its two-hundred day moving average is $35.60. The company has a market capitalization of $3.67 billion, a price-to-earnings ratio of 61.27, a price-to-earnings-growth ratio of 1.53 and a beta of 1.48.
Progyny (NASDAQ:PGNY – Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The company had revenue of $269.94 million during the quarter, compared to analyst estimates of $274.08 million. During the same period in the prior year, the firm earned $0.03 earnings per share. The business’s quarterly revenue was up 26.0% on a year-over-year basis. On average, equities research analysts predict that Progyny, Inc. will post 0.7 earnings per share for the current year.
Institutional Trading of Progyny
Analyst Ratings Changes
PGNY has been the topic of a number of recent research reports. Leerink Partnrs reissued an “outperform” rating on shares of Progyny in a report on Monday, February 26th. Cantor Fitzgerald restated an “overweight” rating and set a $48.00 price objective on shares of Progyny in a research report on Wednesday, February 28th. KeyCorp reduced their target price on Progyny from $45.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 28th. Truist Financial lowered their price target on Progyny from $47.00 to $46.00 and set a “buy” rating for the company in a research report on Wednesday, February 28th. Finally, Barclays began coverage on shares of Progyny in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $48.00 price objective for the company. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $48.30.
Read Our Latest Research Report on PGNY
About Progyny
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Further Reading
- Five stocks we like better than Progyny
- ESG Stocks, What Investors Should Know
- Krispy Kreme’s Sweet Deal: McDonald’s Partnership Sparks Growth?
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- Health Care Stocks Explained: Why You Might Want to Invest
- 7 Stocks That Will Drive the Weight Loss Drugs Market
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.